The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2022 | MRD evaluation: how, when and for which goal?
Jesús San Miguel
• 13 May 2022
Jesús San Miguel, MD, PhD, University of Navarra, Pamplona, Spain, discusses the importance of using measurable residual disease (MRD) to guide therapy in multiple myeloma, and further explains how monitoring disease progression with MRD is the best way to ensure that patients are provided with the best treatment approach. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
